![Markwin P. Velders](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Markwin P. Velders
Direttore/Membro del Consiglio presso ISA Pharmaceuticals BV
Posizioni attive di Markwin P. Velders
Società | Posizione | Inizio | Fine |
---|---|---|---|
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Direttore/Membro del Consiglio | 03/09/2019 | - |
Amarna Therapeutics BV
![]() Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Direttore/Membro del Consiglio | 30/10/2020 | - |
Storia della carriera di Markwin P. Velders
Precedenti posizioni note di Markwin P. Velders
Società | Posizione | Inizio | Fine |
---|---|---|---|
SomantiX BV
![]() SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Amministratore Delegato | - | - |
Formazione di Markwin P. Velders
University of Leiden | Doctorate Degree |
Statistiche
Distribuzione geografica
Paesi Bassi | 5 |
Posizioni
Director/Board Member | 2 |
Doctorate Degree | 1 |
Chief Executive Officer | 1 |
Settori
Consumer Services | 2 |
Commercial Services | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
SomantiX BV
![]() SomantiX BV Miscellaneous Commercial ServicesCommercial Services SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands. | Commercial Services |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |
Amarna Therapeutics BV
![]() Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |
- Borsa valori
- Insiders
- Markwin P. Velders
- Esperienza